Fortune MNC 500 India 2026 edition
Rank#117- Total income
- ₹6,902 Cr
- Profit
- ₹-954 Cr
Last year #74
Mylan Laboratories Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹7,503.56 Cr
▼ 23% YoY
Net loss · FY 2025
₹954.29 Cr
Net margin -12.7%
EBITDA · FY 2025
₹44.78 Cr
EBITDA margin 0.6%
Authorised capital
₹125 Cr
Registered with MCA
Paid-up capital
₹48.7 Cr
Issued & subscribed
Satisfied charges
₹5,501.38 Cr
No open charges
Company age
42 yrs
Est. 1984
Employees · EPFO
11,193
Provident fund records
About Mylan Laboratories Limited
Data last updated:
Mylan Laboratories Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Mp Laboratories (Mauritius) Ltd. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 29 November 1984 and has been in existence for over 42 years.
Mylan Laboratories is ranked #117 on the Fortune MNC 500 India (2026).
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24231TG1984PLC005146. Its GSTIN is 36AADCM3491M1Z2 (Telangana). The company holds 17 GST registrations, of which 14 are active.
The company has an authorised share capital of ₹125 Cr and a paid-up capital of ₹48.7 Cr. It was formerly known as Herren Drugs P Ltd and Matrix Laboratories Limitted. It is led by directors including Arvind Shankar Kanda (Whole-Time Director) and Sarada Kalyani Bhagawati (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No.564/A/22 Road No.92 Jubilee Hills, Hyderabad, Telangana, India – 500096.
As per the financials filed for FY 2025, the company reported a revenue of ₹7,503.56 Cr, a decline of 23% compared to the previous year. For the same year it recorded a net loss of ₹954.29 Cr (net margin -12.7%) and EBITDA of ₹44.78 Cr (EBITDA margin 0.6%). Revenue has declined at a compounded annual rate (CAGR) of 14% over three years and 10% over five years.
The company has about 11,193 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Viatris. As per MCA filings, the company has satisfied charges of ₹5,501.38 Cr on record. Court records list 231 cases involving the company, including 138 filed by the company and 94 filed against it; 44 cases are pending. The company has 12 deals on record (4 funding rounds, 4 secondary share transfers, 3 debt financings), with disclosed funding of ₹13,249 Cr; the latest was in May 2025. Its 9 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Divi's Laboratories Limited with revenue of ₹9,712 Cr. The company has 14 MSME Form 1 returns on record between 2018 and 2024, listing 758 overdue payments to 260 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website viatris.com.
Company details
CIN U24231TG1984PLC005146
Registration Number 005146
Incorporation Date 29 November 1984
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Mp Laboratories (Mauritius) Ltd
Compliance Status Active Compliant
Name history
Mylan Laboratories has undergone 4 name changes throughout its history. The current legal name is Mylan Laboratories Limited.
| Company Name | Status |
|---|---|
| Mylan Laboratories Limited | Current |
| Herren Drugs P Ltd | Previous |
| Matrix Laboratories Limitted | Previous |
| Herren Drugs Ltd | Previous |
| Herren Drugs & Pharmaceuticals Ltd | Previous |
CIN history
Mylan Laboratories has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24231TG1984PLC005146, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231TG1984PLC005146 | Current |
| U24231AP1984PLC005146 | Previous |
| L24231AP1984PLC005146 | Previous |
Key People
Arvind Shankar Kanda Whole-Time Director Sarada Kalyani Bhagawati Whole-Time Director Rajiv Malik Director Recognitions & Rankings of Mylan Laboratories
Contact details
Mylan Laboratories Limited's registered office is in Hyderabad, Telangana. Its website is viatris.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No.564/A/22 Road No.92 Jubilee Hills, Hyderabad, Telangana, India – 500096
- IndustryPharma, API Manufacturers, Drug Formulation & Development
To see the full contact details of Mylan Laboratories Limited, buy the company report.
Comprehensive company report
Mylan Laboratories Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Mylan Laboratories operates one associated brand: Viatris. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Branded pharmaceuticals are developed and commercialized by Viatris internationally. | viatris.com |
Business activity
The main business activity of Mylan Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Mylan Laboratories Limited, buy the company report.
Financials of Mylan Laboratories Limited
FY 2025 filings availableMylan Laboratories Limited reported revenue of ₹7,503.56 Cr (down 23% YoY) for FY 2025.
Revenue · FY 2025
₹7,503.56 Cr ▼ 23%
Net loss · FY 2025
₹954.29 Cr margin -12.7%
EBITDA · FY 2025
₹44.78 Cr margin 0.6%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 23%
3 years · compounded
▼ 14%
5 years · compounded
▼ 10%
EBITDA CAGR growth
1 year
▼ 97%
3 years · compounded
▼ 72%
5 years · compounded
▼ 55%
Revenue has declined at a compounded annual rate (CAGR) of 10% over five years, including a 23% fall in the latest year. EBITDA fell 97% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹44.78 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹954.29 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 0.6% | ||||
| Net Profit Margin | -12.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Mylan Laboratories Limited, buy the company report.
Board of directors of Mylan Laboratories Limited
Mylan Laboratories has 6 current directors and 22 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajiv Malik | Director | 28 Jul 2005 | 21 Years 2 Months | Current |
| Akshay Nanda | Director | 01 Mar 2024 | 2 Years 7 Months | Current |
| Arvind Shankar Kanda | Whole-Time Director | 28 Mar 2024 | 2 Years 6 Months | Current |
| Ramya Suresh | Director | 25 Apr 2024 | 2 Years 5 Months | Current |
| Sarada Kalyani Bhagawati | Whole-Time Director | 01 Nov 2014 | 11 Years 11 Months | Current |
| Nagaraj Goud Bodige Also directs: Famy Life Sciences Private Limited | Nodal Officer | 22 Nov 2022 | 3 Years 11 Months | Current |
Peer comparison
Mylan Laboratories Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Divi's Laboratories Limited | ₹9,712 Cr (FY 2025) | 19.0% | Hyderabad, Telangana, India | |||
| Macleods Pharmaceuticals Ltd | ₹9,671.68 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Ipca Laboratories Limited | ₹9,032.39 Cr (FY 2025) | 15.0% | Mumbai, Maharashtra, India | |||
| Deccan Fine Chemicals (India) Private Limited | ₹8,738.51 Cr (FY 2024) | -1.0% | Hyderabad, Telangana, India | |||
| Emcure Pharmaceuticals Limited | ₹7,963.26 Cr (FY 2025) | 19.0% | Pune, Maharashtra, India | |||
| Mylan Laboratories Limitedthis company | ₹7,503.56 Cr (FY 2025) | -₹954.29 Cr | -12.7% | -23.0% | 11,193 | Hyderabad, Telangana, India |
| Apitoria Pharma Private Limited | ₹6,811.62 Cr (FY 2025) | 20.0% | Hyderabad, Telangana, India | |||
| MSN Laboratories Private Limited | ₹6,761.18 Cr (FY 2024) | 27.0% | Hyderabad, Telangana, India | |||
| Alembic Pharmaceuticals Limited | ₹6,714.63 Cr (FY 2025) | 7.0% | Vadodara, Gujarat, India | |||
| Gland Pharma Ltd | ₹5,830.11 Cr (FY 2025) | 0.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Mylan Laboratories Limited, buy the company report.
Auditor
Mylan Laboratories Limited is audited by DELOITTE HASKINS & SELLS for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DELOITTE HASKINS & SELLS | FY 2023 | 008072S |
Shareholding
The shareholding of Mylan Laboratories Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Mylan Laboratories Limited, buy the company report.
Charges & borrowings
Open charges
None
Satisfied charges
₹5,501.38 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 11 Jun 2013 | 10430983 | Icici Bank Limited | ₹170 Cr | Satisfied | |
| 27 Nov 2012 | 10485829 | Yes Bank Limited | ₹40 Cr | Satisfied | |
| 08 Oct 2012 | 10380757 | Export - Import Bank of India | ₹150 Cr | Satisfied | |
| 18 Jul 2012 | 10373581 | The Ratnakar Bank Limited | ₹50 Cr | Satisfied | |
| 10 Jul 2012 | 10365980 | Yes Bank Limited | ₹60 Cr | Satisfied |
To see the full charge records of Mylan Laboratories Limited, buy the company report.
Total charge records: 55 View all charges
Deals & funding
Mylan Laboratories Limited has 12 deals on record (4 funding rounds, 4 secondary share transfers, 3 debt financings), with disclosed funding of ₹13,249 Cr; the latest was in May 2025.
Total deals
12
Funding rounds
4
Secondary share transfers
4
Debt financings
3
Convertible or debt financing
1
Disclosed funding
₹13,249 Cr
Deals on record (5 of 12)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2025 | Debt financing | ₹800 Cr | Investors: Utah Acquisition Sub INC |
| Sep 2023 | Debt financing | ₹1,000 Cr | Investors: Mylan Luxembourg S.a.r.l |
| Dec 2016 | Secondary share transfer | Undisclosed | Buyer: MP Laboratories (Mauritius) Limited Seller: Merrill Lynch, ESOP Trust - Mylan Laboratories Limited, Others-Mylan Laboratories Limited, an individual |
| Nov 2015 | Funding round | ₹2,476.88 Cr | Investors: Mylan Group B.V |
| Nov 2015 | Debt financing | ₹2,480.34 Cr | Investors: Mylan Luxembourg S.a.r.l |
To see the full deal history of Mylan Laboratories Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Mylan Laboratories Limited has 231 court cases on record: 138 filed by Mylan Laboratories, 94 filed against it. 44 cases are pending and 187 are disposed.
Total cases
231
Filed by the company
138
Filed against the company
94
Pending
44
Disposed
187
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 155 | 43 | 38 |
| District courts | 66 | 47 | 6 |
| Supreme Court | 5 | 4 | 0 |
| NCLT | 5 | 0 | 0 |
Cases on record (5 of 231)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TELANGANA | Arbitration matter | Filed against the company by M/S. Lindstrom Services India Private Limited | Disposed |
| High Court, ANDHRAPRADESH | Appeal | Filed against the company by Eastern Power Distribution Company of Andhra Pradesh Ltd., and 1 other | Disposed |
| High Court | Court case ((T)CMA(TM)) | Filed against the company by Glenmark Pharmaceuticals Limited | Disposed |
| High Court, ANDHRAPRADESH | Writ petition | Filed by the company against Eastern Power Distribution Company of Andhra Pradesh Ltd and 1 other | Disposed |
| High Court, TELANGANA | Writ petition | Filed against the company by Mylan Laboratories Ltd. Workers Union | Disposed |
To see the full case history of Mylan Laboratories Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Mylan Laboratories Limited was last rated by Crisil on 16 Dec 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 16 Dec 2020 |
To see the full credit ratings and regulatory alerts of Mylan Laboratories Limited, buy the company report.
MSME payment delays
Mylan Laboratories Limited has 14 MSME Form 1 returns on record between 2018 and 2024, listing 758 overdue payments to 260 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 260)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Ultra Instruments | |||
| Kiran Elastomers Private Limited | |||
| The Master Packaging | |||
| Rank Organics Chemical Private Limited | |||
| Jeet Electronics and Engineering (India) Pvt Ltd |
To see the full MSME payment records of Mylan Laboratories Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Mylan Laboratories Limited has a workforce of 11,193 employees on its EPFO records as of Mar 25, 2024, across 11 active EPFO establishments.
Employee count
11,193
Active EPFO establishments
11
Employee growth
0.36%
GST
Mylan Laboratories has 17 GST registrations: 14 active and 3 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
17
Active
14
Cancelled / inactive
3
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AADCM3491M1Z2 | Telangana | Active | 01 Jul 2017 |
| 36AADCM3491M2Z1 | Telangana | Active | 10 Jul 2017 |
| 36AADCM3491M3Z0 | Telangana | Active | 19 Jul 2017 |
| 23AADCM3491M1Z9 | Madhya Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Mylan Laboratories Limited, buy the company report.
Recent activity
Mylan Laboratories Limited has 28 board changes on record since 2005: 6 appointments and 22 cessations. The latest: Akshay Nanda ceased to be Additional Director on 19 May 2024.
AGM
Mylan Laboratories Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Mylan Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Ceased
Akshay Nanda ceased to be Additional Director.
Ceased
Arvind Shankar Kanda ceased to be Additional Director.
Ceased
Ramya Suresh ceased to be Additional Director.
Appointed
Ramya Suresh was appointed as Director.
Appointed
Arvind Shankar Kanda was appointed as Whole-Time Director.
Appointed
Akshay Nanda was appointed as Director.
Appointed
Nagaraj Goud Bodige was appointed as Nodal Officer.
Ceased
Mohit Saraf ceased to be Additional Director.
Ceased
Rajiv Krishan Luthra ceased to be Additional Director.
Charges
A charge registered on 12 Apr 2005 via Charge ID 90128817 with Andhra Bank was fully satisfied on 11 Dec 2014.
155 earlier events are in the company report.
News
Frequently asked questions
Mylan Laboratories is an active public limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 29 November 1984 (42+ years old) and is registered under CIN U24231TG1984PLC005146.
Mylan Laboratories has 6 current directors:
- Arvind Shankar Kanda - Whole-Time Director
- Sarada Kalyani Bhagawati - Whole-Time Director
- Rajiv Malik - Director
- Akshay Nanda - Director
- Ramya Suresh - Director
- Nagaraj Goud Bodige - Nodal Officer
The latest financial statements of Mylan Laboratories on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Mylan Laboratories is 36AADCM3491M1Z2, registered in Telangana. The company has 17 GST registrations in all, of which 14 are active and 3 are cancelled or inactive. Other active GSTINs include 36AADCM3491M2Z1 (Telangana), 36AADCM3491M3Z0 (Telangana), 23AADCM3491M1Z9 (Madhya Pradesh).
The CIN (Corporate Identification Number) of Mylan Laboratories is U24231TG1984PLC005146. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Mylan Laboratories has 231 court cases on record: 138 filed by the company and 94 filed against it. 44 are pending. Most are in the high courts.
Mylan Laboratories was incorporated on 29 November 1984, making it 42+ years old. It is registered with the Registrar of Companies, Hyderabad.
Mylan Laboratories has 12 deals on record (4 funding rounds, 4 secondary share transfers, 3 debt financings), with disclosed funding of ₹13,249 Cr; the latest was in May 2025.
The peers of Mylan Laboratories by revenue are Divi's Laboratories Limited, Macleods Pharmaceuticals Ltd, Ipca Laboratories Limited, Deccan Fine Chemicals (India) Private Limited, Emcure Pharmaceuticals Limited and 4 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Akshay Nanda ceased to be Additional Director on 19 May 2024. Arvind Shankar Kanda ceased to be Additional Director on 19 May 2024. Ramya Suresh ceased to be Additional Director on 19 May 2024. Mylan Laboratories has 28 board changes on record in total.
Mylan Laboratories has 14 MSME Form 1 returns on record between 2018 and 2024, listing 758 overdue payments to 260 micro and small suppliers. The latest return was filed on 26 Apr 2024.
Mylan Laboratories can be reached through the website viatris.com. Its registered office is in Hyderabad, Telangana, India.